Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
Abstract Background and Aim Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods Entecavir (ETV) and TAF were given to 66...
Main Authors: | Kento Inada, Shun Kaneko, Masayuki Kurosaki, Koji Yamashita, Sakura Kirino, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | JGH Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgh3.12636 |
Similar Items
-
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01) -
Efficacy of tenofovir alafenamide in treatment of hepatitis B virus: A meta-analysis and non-inferiority evaluation
by: Qiu-Ran Wang, et al.
Published: (2021-06-01) -
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01) -
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01) -
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01)